FOXP3 and neoplasm: Results for the expression of the Foxp3 gene in the tumor microenvironment showed that after 4 weeks of oral administration with Cyclophosphamide, there was a significant decrease in Foxp3 gene expression compared to glucomannan at 2 and 4 mg doses and the PBS group (p < 0.05, p < 0.05, and p = 0.0079, respectively).